Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 138
Filter
1.
Pancreatology ; 17(4): 572-579, 2017.
Article in English | MEDLINE | ID: mdl-28600220

ABSTRACT

BACKGROUND/OBJECTIVES: The epidemiology, natural history, complications, and therapeutic management of chronic pancreatitis (CP) are not well described at the national level. This multi-centre prospective observational study involving eight Belgian hospitals aimed to improve the understanding of these aspects of CP in Belgium. METHODS: All patients with a diagnosis of CP based on imaging were eligible for this study. Data were gathered regarding epidemiology, etiology, CP complications, and treatment modalities. RESULTS: A total of 809 patients were included between 1/9/2014 and 31/8/2015. Most patients (794) were adults ≥16-years old, 74% were male, the median age at symptom onset was 47 (38-57) years, the median disease duration was 7 (3-13) years, and the median Izbicki pain score (IPS) was 96 (0-195). The main etiological risk factors according to the TIGAR-O classification were alcohol and tobacco (67%). Current drinkers had lower body mass index (BMI) (21.4 kg/m2 vs 24.1 kg/m2), higher IPS (110 vs 56), and longer inability to work than non-drinkers. Current smokers had lower BMI (21.5 kg/m2 vs 25 kg/m2) and higher IPS (120 vs 30) than non-smokers. Endocrine insufficiency and/or clinical steatorrhea was recorded in 41% and 36% of patients, respectively. The highest IPS was reported in patients with ongoing endotherapy (166 vs 50 for patients who completed endoscopy). CONCLUSION: This multicentric study on CP patients showed that current alcohol drinking and smoking are associated with pain and malnutrition. Pain scores were higher in patients with ongoing endotherapy, independently of surgery.

2.
Aliment Pharmacol Ther ; 43(5): 612-20, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26748470

ABSTRACT

BACKGROUND: Approximately 20% of primary sclerosing cholangitis (PSC) patients with concomitant inflammatory bowel disease (IBD) have Crohn's disease (CD). AIM: To compare PSC/CD with other PSC patients. METHODS: Retrospective study of 240 PSC patients diagnosed between 1975 and 2012 (median follow-up 12 years). Activity of PSC at diagnosis was assessed by liver biopsy, Mayo risk and ERC scores. Survival without liver transplantation, number of transplantations and liver-related death were endpoints. RESULTS: Sixty-three per cent of patients had IBD: 105 UC, 32 CD and 14 IBD unclassified (IBDu). IBD was diagnosed before PSC in 50%. The yearly development of PSC after diagnosing IBD was similar in UC, CD or IBDu. Small-duct PSC was present in 28% of PSC/CD compared to 3% of PSC/UC. Small-duct PSC had a markedly better survival than large-duct PSC: no patient developed cholangiocarcinoma or liver-related death, but colorectal cancer occurred in three patients. In large-duct PSC, a more favourable outcome was evident in patients with CD. The liver disease was less progressive: one patient underwent liver transplantation compared to 28% and liver-related deaths were absent compared to 7% in the other PSC groups. CONCLUSIONS: The prevalence of PSC with concomitant Crohn's disease is relatively rare, but the outcome is more benign than PSC with UC or without IBD. Approximately one-fourth has small-duct PSC. In large-duct PSC/CD, liver disease is less aggressive and the outcome is much better. The outcome of PSC patients with UC resembled that of PSC without IBD.


Subject(s)
Cholangitis, Sclerosing/epidemiology , Colitis, Ulcerative/epidemiology , Crohn Disease/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Child , Child, Preschool , Cholangitis, Sclerosing/classification , Cholangitis, Sclerosing/mortality , Cholangitis, Sclerosing/surgery , Colorectal Neoplasms/complications , Female , Humans , Inflammatory Bowel Diseases/epidemiology , Liver Transplantation , Male , Middle Aged , Prevalence , Retrospective Studies , Young Adult
3.
Acta Gastroenterol Belg ; 78(3): 299-305, 2015.
Article in English | MEDLINE | ID: mdl-26448411

ABSTRACT

BACKGROUND AND STUDY AIMS: The Budd-Chiari syndrome is a rare disorder characterized by hepatic venous outflow obstruction. A step-wise management was recently proposed. The aim of this study is to reassess our treatment approach and long-term outcome. PATIENTS AND METHODS: The data of 37 Budd-Chiari patients, seen in our unit, were critically analyzed and compared with the ENVIE (European Network For Vascular Disorders of the Liver) data. RESULTS: Most patients had multiple prothrombotic conditions (41%), of which an underlying myeloproliferative neoplasm was the most frequent (59%). The JAK2V617F mutation was associated with more complete occlusion of all hepatic veins (JAK2 mutation +: 70% vs JAK2 mutation -: 23% and a higher severity score. The step-wise treatment algorithm used in our unit, in function of the severity of the liver impairment and the number and the extension of hepatic veins occluded, resulted in the following treatments: only anticoagulation (n = 7.21%), recanalization procedure (n = 4.21%), portosystemic shunts (n = 9.26%) and liver transplantation (n = 14.44%). This resulted in a 10 year survival rate of 90%. Treatment of the underlying hemostatic disorder offered a low recurrence rate. None of the 21 patients with a myeloproliferative neoplasm died in relation to the hematologic disorder. CONCLUSIONS: An individualized treatment regimen consisting of anticoagulation and interventional radiology and/or transplantation when necessary and strict follow-up of the underlying hematologic disorder, provided an excellent long-term survival, which confirm the data of the ENVIE study.

4.
JBR-BTR ; 97(6): 361-3, 2014.
Article in English | MEDLINE | ID: mdl-25786295

ABSTRACT

A 28-year-old patient admitted with jaundice, vomiting and deteriorating coagulopathy was diagnosed with acute liver failure. After listing for urgent transplantation, he developed Boerhaave's syndrome and massive hemobilia, two life-threatening complications. Massive hemobilia secondary to a fistula between the right hepatic artery and the right bile duct occurred several days after transjugular biopsy and was controlled with fluid resuscitation, transfusion and arterial embolization. Two days later he was transplanted successfully, and is currently doing well after more than 72 months. Aggressive treatment of potentially reversible complications during acute liver failure whilst awaiting transplantation is mandatory to allow survival of these patients.


Subject(s)
Embolization, Therapeutic , Hemobilia/therapy , Liver Failure, Acute/complications , Adult , Humans , Male , Tomography, X-Ray Computed
5.
Transplant Proc ; 44(9): 2857-60, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23146542

ABSTRACT

INTRODUCTION: Advanced liver disease is characterized by prolonged global coagulation tests such as prothrombin time (PT). Using Model of End-stage Liver Disease (MELD) score-based allocation, many current transplant recipients show advanced end-stage liver disease with an elevated international normalized ratio (INR). The relationship between abnormalities in coagulation tests and the risk of bleeding has been recently challenged among liver disease patients. In this study we reassessed risk factors for bleeding and the clinical implications for patients who underwent orthotopic liver transplantation (OLT). METHODS: We studied OLT patients between 2005 and 2011 excluding combined transplantations, retransplantations, or cases due to acute liver failure. We collected prospectively pre-OLT, during OLT, and post-OLT clinical and biochemical data to assess the risk for bleeding using linear regression models. RESULTS: The strongest predictor of overall survival among 286 patients with a mean follow-up of 32 months was the number of blood transfusions (P = .005). The risk factor for bleeding during surgery investigated by multivariate analysis only showed the INR (P < .001) and the presence of ascites (P = .003) to independently correlate with the amount of blood transfusion. Receiver operation characteristics (ROC) analysis performed to determine the risk for massive blood transfusion (more than 6 units) revealed a cut-off value for INR ≥ 1.6. Appreciation of the operative field by the surgeon during the intervention as "wet" versus "dry", amounts of blood transfusion and fresh frozen plasma, and stay in the intensive care unit (ICU) and in the hospital were all significantly different (P < .001) for patients with INR <1.6 versus INR ≥ 1.6. CONCLUSIONS: Bleeding during OLT affects the outcome. The risk is independently influenced by the presence of ascites (probably reflecting the degree portal hypertension) and an INR ≥ 1.6. To improve survival after OLT therapeutic interventions should be further explored to reduce the need for blood transfusions.


Subject(s)
Blood Coagulation Disorders/complications , Blood Loss, Surgical/prevention & control , Liver Diseases/surgery , Liver Transplantation/adverse effects , Adolescent , Adult , Aged , Ascites/etiology , Blood Coagulation Disorders/blood , Blood Coagulation Disorders/diagnosis , Blood Coagulation Disorders/mortality , Blood Coagulation Tests , Blood Loss, Surgical/mortality , Blood Transfusion , Female , Humans , Kaplan-Meier Estimate , Linear Models , Liver Diseases/complications , Liver Diseases/diagnosis , Liver Diseases/mortality , Liver Transplantation/mortality , Male , Middle Aged , Multivariate Analysis , Prospective Studies , Risk Factors , Time Factors , Treatment Outcome , Young Adult
6.
Transplant Proc ; 44(9): 2861-7, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23146543

ABSTRACT

BACKGROUND: Wider utilization of liver grafts from donors ≥ 70 years old could substantially expand the organ pool, but their use remains limited by fear of poorer outcomes. We examined the results at our center of liver transplantation (OLT) using livers from donors ≥ 70 years old. METHODS: From February 2003 to August 2010, we performed 450 OLT including 58 (13%) using donors ≥ 70 whose outcomes were compared with those using donors <70 years old. RESULTS: Cerebrovascular causes of death predominated among donors ≥ 70 (85% vs 47% in donors <70; P < .001). In contrast, traumatic causes of death predominated among donors <70 (36% vs 14% in donors ≥ 70; P = .002). Unlike grafts from donors <70 years old, grafts from older individuals had no additional risk factors (steatosis, high sodium, or hemodynamic instability). Both groups were comparable for cold and warm ischemia times. No difference was noted in posttransplant peak transaminases, incidence of primary nonfunction, hepatic artery thrombosis, biliary strictures, or retransplantation rates between groups. The 1- and 5-year patient survivals were 88% and 82% in recipients of livers <70 versus 90% and 84% in those from ≥ 70 years old (P = .705). Recipients of older grafts, who were 6 years older than recipients of younger grafts (P < .001), tended to have a lower laboratory Model for End-Stage Liver Disease score (P = .074). CONCLUSIONS: Short and mid-term survival following OLT using donors ≥ 70 yo can be excellent provided that there is adequate donor and recipient selection. Septuagenarians and octogenarians with cerebrovascular ischemic and bleeding accidents represent a large pool of potential donors whose wider use could substantially reduce mortality on the OLT waiting list.


Subject(s)
Donor Selection , Liver Transplantation , Tissue Donors/supply & distribution , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Belgium , Cause of Death , Child , Child, Preschool , Female , Humans , Kaplan-Meier Estimate , Liver Transplantation/adverse effects , Liver Transplantation/mortality , Male , Middle Aged , Postoperative Complications/mortality , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Waiting Lists , Young Adult
7.
Transplant Proc ; 44(9): 2868-73, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23146544

ABSTRACT

INTRODUCTION: Orthotopic liver transplantation (OLT) (LTx) using donation after circulatory death (DCD) donors is increasingly performed, but still considered to risk of poorer outcomes compared with standard donations after brain death (DBD)-OLT. Therefore we reviewed our results of DCD-OLT. PATIENTS AND METHODS: Between 2003 and 2010, we performed 30 DCD-OLT (6% of all OLT). We retrospectively reviewed medical records of donors and recipients after DCD versus DBD-OLT to analyze biliary complications, retransplantation rates, and patient/graft survivals. RESULTS: Median donor age was similar for DCD and DBD-OLT: 51 versus 53 years (P = .244). Median donor warm ischemia time (stop ventilation to cold perfusion in DCD donors) was 24 minutes. Median cold ischemia time was shorter for DCD (6 hours 54 minutes) compared with DBD-OLT (8 hours 36 minutes; P < .0001). Median laboratory model of end-stage liver disease score was 15 for DCD, and 16 for DBD-OLT (P = .59). Median post-OLT Aspartate Aminotransferase (AST) peak was higher after DCD: 1178 versus DBD-OLT 651 IU/L (P = .005). The incidence of nonanastomotic strictures was different: 33.3% for DCD versus 12.5% for DBD-OLT (P = .001). The overall retransplantation rate was 3% after both DCD and DBD-OLT. After DCD-LTx actuarial 1, 3- and 5-year patient survivals were 93, 85 and 85%, and corresponding graft survivals, 90%, 82%, and 82% respectively, and not different compared with DBD-OLT: 88%, 78%, and 72% (P = .348) and 85%, 74%, and 68% (P = .524) respectively. CONCLUSION: Despite substantial ischemic injury (high peak AST and biliary strictures) short- and long-term survival after DCD-OLT was comparable to DBD-OLT. Rapid donor surgery, careful donor and recipient selection, as well as short warm and cold ischemia times are key factors to optimize outcomes after DCD-OLT. However, strategies to reduce biliary complications remain warranted.


Subject(s)
Donor Selection , Liver Transplantation , Tissue Donors/supply & distribution , Adult , Aged , Belgium , Cause of Death , Chi-Square Distribution , Cold Ischemia/adverse effects , Female , Graft Survival , Humans , Kaplan-Meier Estimate , Liver Transplantation/adverse effects , Liver Transplantation/mortality , Male , Middle Aged , Postoperative Complications/mortality , Postoperative Complications/surgery , Reoperation , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Warm Ischemia/adverse effects
8.
Acta Chir Belg ; 112(3): 232-3, 2012.
Article in English | MEDLINE | ID: mdl-22808766

ABSTRACT

We present the case of a 50-year-old patient in whom an anastomotic biliary stricture after liver transplantation was treated endoscopically by sphincterotomy, dilatation and stenting using a plastic biliary stent. A distal migration of the stent caused a perforation of the rectum which was treated following stent extraction per anum -- conservatively with antibiotics and temporary bowel rest.


Subject(s)
Intestinal Perforation/diagnosis , Intestinal Perforation/etiology , Liver Transplantation/adverse effects , Rectal Diseases/diagnosis , Rectal Diseases/etiology , Stents/adverse effects , Female , Humans , Intestinal Perforation/therapy , Liver Cirrhosis, Alcoholic/therapy , Liver Transplantation/instrumentation , Middle Aged , Rectal Diseases/therapy
9.
Transplant Proc ; 43(9): 3493-5, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22099826

ABSTRACT

We describe the case of a 26-year-old man with acute liver failure secondary to ingestion of khat (Catha edulis) leaves. In fact, this is the first case of acute liver failure due to khat reported outside the United Kingdom. The combination of specific epidemiologic data (young man of East African origin) and clinical features (central nervous system stimulation, withdrawal reactions, toxic autoimmune-like hepatitis) led to the diagnosis. Mechanisms of action and potential side effects of khat are elaborated on.


Subject(s)
Catha/adverse effects , Liver Failure, Acute/chemically induced , Liver Failure, Acute/therapy , Liver Transplantation/methods , Plant Extracts/adverse effects , Adult , Biopsy , Graft Survival , Humans , Male , Necrosis , Treatment Outcome
10.
Neth J Med ; 69(7): 324-9, 2011.
Article in English | MEDLINE | ID: mdl-21934177

ABSTRACT

We review the sensitivity of different diagnostic tests for breast cancer management based on recent experience in a 34-year-old patient. False-negative tests at diagnosis of early disease and of relapse resulted in diagnostic and therapeutic delays. Initial mammography and breast ultrasonography were falsely negative despite a palpable breast lump. Clinical examination and axillary ultrasound missed macroscopically involved lymph nodes. At relapse, metastatic lesions were missed despite symptoms, three years after primary treatment. CA 15-3 was normal; bone and liver metastases were missed by standard and more advanced imaging techniques including liver ultrasonography, nuclear bone scan and PET -CT scan. Worsening of clinical symptoms, lab results and abnormal tissue biopsies finally led to the diagnosis of extensive metastatic disease. Genetic screening showed an abnormality within the BRCA-1 region of unknown clinical importance. This review highlights 1) that diagnostic tests managing symptomatic breast cancer patients may have a low sensitivity, 2) the importance of clinical findings and other markers for disease, such as lactate dehydrogenase and 3) the need for diagnostic biopsies for clinically suspect symptoms despite normal imaging and biochemistry.


Subject(s)
Breast Neoplasms/diagnosis , Carcinoma, Ductal, Breast/diagnosis , Delayed Diagnosis , Diagnostic Errors , Adult , Biomarkers/metabolism , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/secondary , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/secondary , False Negative Reactions , Fatal Outcome , Female , Humans , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Lymph Node Excision , Mammography , Radionuclide Imaging , Sensitivity and Specificity , Ultrasonography, Mammary
11.
Acta Gastroenterol Belg ; 74(1): 9-16, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21563648

ABSTRACT

INTRODUCTION: Non-alcoholic Fatty Liver Disease (NAFLD) is increasingly recognised as a source of liver related morbidity and mortality. Hard data on epidemiology and natural history are scarce. AIM: To study demographic and metabolic characteristics of the NAFLD patients seen by Belgian hepatologists. METHODS: Belgian hepatologists filled in a questionnaire for every newly diagnosed NAFLD patient between January 1st and December 31st 2004. Liver biopsy was advised if ALT > 1.5 x ULN and if 3/5 of the criteria for the metabolic syndrome (MS) (ATPI-II) were present, but was not mandatory. Biopsy was scored using the Brunt classification. RESULTS: 230 patients were prospectively included in 9 centres; 54% were males; mean age was 49.4 +/- 13.9 y; mean BMI was 30.6 +/- 4.6 kg/m2. The MS was present in 53%. In 16% formerly undiagnosed diabetes was discovered. 51% had a liver biopsy: 25% met the criteria, 26% did not. Grading did not differ between patients with or without MS. Staging was significantly more severe in patients with MS (2.43 +/- 1.25 vs. 1.73 +/- 1.18, p < 0.001). A subgroup of patients with GGT > 5 x ULN were significantly older (55.9 vs. 47.64 y, p = 0.02), more frequently diabetic (53% vs. 23%, p = 0.01) and had more advanced fibrosis (3.42 vs. 1.08, p = 0.008). ALT levels were variable. CONCLUSIONS: The MS is highly prevalent in Belgian NAFLD patients and is associated with more severe disease. Mild to moderate fibrosis is frequent, and the proposed criteria for liver biopsy are not accurate in selecting these patients. Patients with elevated GGT constitute a subgroup with more advanced disease.


Subject(s)
Alanine Transaminase/blood , Fatty Liver , Liver Cirrhosis , Metabolic Syndrome/epidemiology , Metabolic Syndrome/metabolism , Adolescent , Adult , Aged , Belgium/epidemiology , Cohort Studies , Fatty Liver/epidemiology , Fatty Liver/metabolism , Fatty Liver/pathology , Female , Humans , Liver Cirrhosis/epidemiology , Liver Cirrhosis/metabolism , Liver Cirrhosis/pathology , Male , Middle Aged , Prevalence , Registries/statistics & numerical data , Young Adult
12.
Acta Gastroenterol Belg ; 74(1): 82-7, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21563658

ABSTRACT

Endotipsitis or primary infection of a TIPS-stent, is an uncommon but possible life- threatening condition by its potential evolution to sepsis and death. Diagnosis should be suspected in patients with a TIPS-stent presenting with stent-dysfunction associated with fever or relapsing episodes of bacteremia/sepsis without any other alternative focus. A certain diagnosis is made by post-factum histopathological and/or microbiological examination of the TIPS-stent which is only possible after liver transplantation or at autopsy, whereas it can be highly suspected in case of repetitive positive blood-cultures without any other focus in a patient with a TIPS-stent. The microorganisms responsible for endotipsitis are most frequently of Gram-negative enteric origin. The regimen and duration of the treatment should be individualized and depends on multiple factors like the antibiotic sensitivity of the organism and the patients condition. In case of a fungal infection, longer treatment is recommended.


Subject(s)
Escherichia coli Infections/complications , Liver Cirrhosis/surgery , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Prosthesis-Related Infections/complications , Sepsis/etiology , Bacteremia/complications , Humans , Male , Middle Aged , Recurrence
13.
Transplant Proc ; 42(10): 4399-402, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21168707

ABSTRACT

PURPOSE: The aim of this study was to investigate the safety and efficacy of lifelong therapy with intravenous hepatitis B immunoglobulins (i.v. HBIg) to prevent recurrence of hepatitis B after orthotopic liver transplantation (OLT). METHODS: This was a single-center retrospective study of the long-term outcome of 56 patients who were transplanted for active hepatitis B-related liver disease. In addition to i.v. HBIg, patients received antiviral therapy for at least 1 year. RESULTS: 1-, 5-, and 10-year survival rates were 95%, 82%, and 80%, respectively. None of the patients died due to hepatitis B virus (HBV)-related complications. In 3 patients (5%), a hepatitis B surface antigen (HBsAg)-negative status was not reached. All of these patients had a very high viral load at the time of OLT. HBsAg and HBV DNA reappeared in 6 patients (11%): In 1 patient, recurrence occurred 9 months after OLT while still under combination treatment with lamivudine, and 2 patients were temporarily treated abroad with intramuscular HBIg. Only 3 patients suffered from HBV recurrence while under monotherapy with i.v. HBIg. No serious side effects to i.v. HBIg were reported during this long-term follow-up. CONCLUSION: Lifelong administration of i.v. HBIg is safe, and recurrence of HBV disease occurred only in a minority of the patients during long-term follow-up. Prognosis of HBV-related OLT with this therapy is excellent.


Subject(s)
Hepatitis B/prevention & control , Immunoglobulins/administration & dosage , Liver Transplantation , Adult , Aged , Female , Hepatitis B/surgery , Hepatitis B virus/genetics , Hepatitis B virus/isolation & purification , Humans , Male , Middle Aged , Recurrence , Retrospective Studies , Survival Rate , Viral Load
14.
Acta Gastroenterol Belg ; 73(2): 239-46, 2010.
Article in English | MEDLINE | ID: mdl-20690563

ABSTRACT

In a review of the literature concerning autoimmune pancreatitis we had special interest for the concept of IgG4-related pathology as a systemic disease with several clinical manifestations. In general, IgG4-positivity can not only be found in the pancreas, but also at the level of the kidneys, extrahepatic biliary ducts, gallbladder, lungs, salivary glands, lacrimal glands, retroperitoneal tissue, ureters, prostate, meninges and lymph nodes. IgG4 seems to be a central key player in the pathophysiology of this disease.


Subject(s)
Autoimmune Diseases/pathology , Autoimmune Diseases/physiopathology , Pancreatitis/pathology , Pancreatitis/physiopathology , Retroperitoneal Fibrosis/pathology , Humans , Pancreas/pathology , Sclerosis
15.
Acta Gastroenterol Belg ; 73(1): 5-11, 2010.
Article in English | MEDLINE | ID: mdl-20458844

ABSTRACT

BACKGROUND AND STUDY AIMS: Large international clinical trials conducted in the past 5 years rapidly improved the treatment of chronic hepatitis C; however, it is unclear whether the advances seen in clinical trials are being paralleled by similar improvements in routine clinical practice. PegIntrust is a Belgian community-based trial evaluating the sustained virological response. PATIENTS AND METHODS: Observational study of 219 patients receiving pegylated interferon alfa-2b (1.5 microg/kg/wk) and weight-based ribavirin (800-1200 mg/day) for 48 weeks. Primary study end point was sustained virological response (SVR), defined as undetectable HCV RNA 6 months after the completion of treatment. RESULTS: In total, 108 patients (49.3 %) had undetectable HCV RNA at the end of therapy, 91 (41.6%) attaining SVR. Of the 111 patients without an end-of-treatment response, 28 were non-responders, and 21 had virological breakthrough. In total, 134 patients attained early virological response (EVR); 88 (65.7%) of those patients attained SVR. In contrast, 82 (96.5 %) of the 85 patients who did not attain EVR also did not attain SVR. Age, fibrosis score and baseline viral load were identified as important predictors of treatment outcome. The most frequently reported serious adverse events resulting in treatment discontinuation were anemia (n = 10), fatigue/asthenia/malaise (n = 6) and fever (n = 3). CONCLUSION: Our data indicate that treatment of chronic hepatitis C with PEG-IFN alfa-2b plus weight-based ribavirin results in favourable treatment outcomes in a Belgian cohort of patients treated in community-based clinical practice.


Subject(s)
Antiviral Agents/administration & dosage , Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Polyethylene Glycols/administration & dosage , Ribavirin/administration & dosage , Adult , Belgium , Cohort Studies , Drug Therapy, Combination , Female , Humans , Interferon alpha-2 , Male , Middle Aged , Recombinant Proteins , Treatment Outcome
16.
Acta Gastroenterol Belg ; 73(1): 18-24, 2010.
Article in English | MEDLINE | ID: mdl-20458846

ABSTRACT

BACKGROUND AND STUDY AIMS: Endoscopic insertion of a biliary stent is standard practice in the palliative treatment of malignant biliary obstructions. Experience with the new ePTFE-covered Viabil stent is mainly limited to the percutaneous approach. We report our experience with its endoscopic application in patients with distal malignant biliary obstructions. PATIENTS AND METHODS: Eleven patients with an inoperable tumour, without apparent metastatic disease, and with an ECOG score of 0 to 1, were included. All patients received an ePTFE-covered Viabil stent of 10 mm diameter, with transmural side-holes. Primary endpoints were stent patency and patient survival. RESULTS: Overall median patient survival was 220 days; 10 patients died free of jaundice from non-stent related causes. Due to malfunction of the prototype stents at insertion, the introduction of 2 Viabils was required in 3 patients to acquire complete bile duct drainage. Thus, a total of 14 stents was needed in 11 patients. Stent dysfunction occurred in 3/11 patients. It always resulted from massive stone impaction needing stone removal with additional stenting in two out of 3 patients. Stent patency was 80% at 3 and 6 months, and 63% at 9 and 12 months. Lifetime palliation was 73%. CONCLUSIONS: Although the biliary Viabil device has been developed to minimize bacterial adherence and sludge formation, stent dysfunctions in this series always resulted from stone impaction. Moreover, malfunction of the prototype stents needed the insertion of a second stent in 3 patients. Overall life time palliation was 73%. Further experience with newer versions of the device as well as comparative studies versus other metallic stents are needed.


Subject(s)
Cholestasis/therapy , Constriction, Pathologic/therapy , Endoscopy , Polytetrafluoroethylene/analogs & derivatives , Stents , Adult , Aged , Aged, 80 and over , Cholestasis/etiology , Cholestasis/pathology , Constriction, Pathologic/etiology , Constriction, Pathologic/pathology , Feasibility Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies , Treatment Outcome
18.
Surg Endosc ; 24(2): 413-6, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19554369

ABSTRACT

BACKGROUND: In the era of cost-conscious healthcare, hospitals are focusing on costs. Analysis of hospital costs per cost category may provide indications for potential cost-saving measures in the management of common bile duct stones (CBDS) with gallbladder in situ. METHODS: Between October 2005 and September 2006, 53 consecutive patients suffering from CBDS underwent either a one-stage procedure [laparoscopic common bile duct exploration (LCBDE) with stone clearance and cholecystectomy (LCCE)] or a two-stage procedure [endoscopic retrograde cholangiopancreatography with sphincterotomy and stone clearance (ERCP/ERS) followed by LCCE]. Costs were defined in different cost categories for each activity centre and were linked to the individual patient via the "bill of activities". Only patients (n = 38) with an uneventful post-procedural course and with available cost data were considered for cost analysis. Total length of hospital stay (LOS) was 2 (0-6) days after one-stage and 8 (3-18) days after two-stage procedure (p < 0.0001). RESULTS: Costs per patient were significantly (p < 0.0001) less after one-stage versus two-stage management, i.e. total hospital costs (euro2,636 versus euro4,608), hospitalisation costs (euro701 versus euro2,190), consumables/pharmacy (euro645 versus euro1,476) and para-medical personnel (euro1,035 versus euro1,860; p = 0.0002). Operation room (OR) costs were comparable for one-stage and two-stage management (euro1,278 versus euro1,232; p = 0.280). Total hospital costs during ERCP were euro2,648 (euro729-4,544), during LCCE without LCBDE were euro2,101 (euro1,033-4,269), and during LCCE with LCBDE were euro2,636 (euro1,176-4,235). CONCLUSION: In the management of patients with CBDS and gallbladder in situ a one-stage procedure is associated with significantly less costs as compared with a two-stage procedure. From the economical point of view these patients should preferably be treated via a one-stage procedure as long as safety and efficacy of this approach are provided.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde/economics , Cholecystectomy, Laparoscopic/economics , Choledocholithiasis/surgery , Hospital Costs/statistics & numerical data , Sphincterotomy, Endoscopic/economics , Adult , Aged , Aged, 80 and over , Belgium , Cost Savings , Costs and Cost Analysis , Female , Hospitals, University/economics , Humans , Length of Stay/economics , Male , Middle Aged , Young Adult
19.
Transplant Proc ; 41(8): 3399-402, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19857757

ABSTRACT

Biliary strictures (BS), a major complication after orthotopic liver transplantation (OLT), cause morbidity, mortality, graft loss, and increased costs. The virtually unchanged incidence of BS (approximately 10%-25%) suggests that they are not simply "technical" in origin, but probably represent a mucosa ischemic injury inherent in the transplantation procedure. To study risk factors for BS, we analyzed 403 OLTs performed between January 1, 1997 and December 31, 2006, at a single center, excluding cases of regraft or death within 1 month. The average time to the diagnosis of the BS was 253 days (range, 7-1002 days). Upon univariate analysis, the absence of flushing of donor bile ducts, an imported versus a locally procured liver, and rejection were risk factors for BS. In contrast, the following factors were protective: donor cardiac arrest followed by resuscitation (suggesting an ischemic preconditioning effect) as well as addition of epoprostenol to and pressurization of the preservation solution. Patients with higher postoperative peak values of transaminases, bilirubin, alkaline phosphatase, and gamma glutamyl transpeptidase were at greater risk for later development of BS. Donor hypotension, donor age, donor intensive care unit (ICU) stay, type of preservation, positive cross-match, cold and warm ischemia times, sequential versus simultaneous portal/arterial reperfusion, as well as cytomegalovirus (CMV) infection were not risk factors for BS. Upon multivariate analysis, only epoprostenol and pressurization offered protection from BS. In conclusion, this study 2 novel points: (1) patients with high(er) transaminase values and cholestasis early postoperatively are at greater risk to develop later BS and require close monitoring and (2) donor maneuvers for better flushing and preserving peribiliary vascular plexus and biliary mucosa (epoprostenol and pressurization of preservation solution) offer protection from BS.


Subject(s)
Biliary Dyskinesia/epidemiology , Epoprostenol/therapeutic use , Liver Transplantation/adverse effects , Adult , Analysis of Variance , Antihypertensive Agents/therapeutic use , Bile Ducts/drug effects , Bile Ducts/physiology , Biliary Dyskinesia/prevention & control , Humans , Intensive Care Units , Length of Stay , Liver Transplantation/mortality , Platelet Aggregation Inhibitors/therapeutic use , Retrospective Studies , Risk Factors , Survival Analysis , Survivors
20.
Transplant Proc ; 41(8): 3427-9, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19857762

ABSTRACT

A 53-year-old man with alcoholic liver cirrhosis underwent orthotopic liver transplantation (OLT) using a marginal graft. Persistent cholestasis post-OLT was successfully treated using a molecular adsorbent recirculating system (MARS). Afterwards, the patient developed refractory ascites, which was controlled by a transjugular intrahepatic portosystemic shunt (TIPS). TIPS reduction and eventually occlusion was necessary due to the development of encephalopathy. Despite TIPS occlusion, the ascites did not relapse probably because of the onset of other adaptive mechanisms. MARS and TIPS used sequentially were capable of rescuing a liver graft, thereby avoiding the morbidity and mortality associated with early retransplantation and sparing a liver graft from the donor pool.


Subject(s)
Liver Cirrhosis, Alcoholic/surgery , Liver Transplantation/methods , Portasystemic Shunt, Surgical/methods , Ascites/etiology , Assisted Circulation/methods , Cholestasis/etiology , Chronic Disease , Humans , Male , Middle Aged , Postoperative Complications/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...